Immunotherapy and chemo join forces against tough lymphoma
NCT ID NCT03011814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs—durvalumab (an immunotherapy) and lenalidomide (a chemotherapy drug)—alone or together in people with T-cell lymphoma that has returned or not responded to prior treatment. The goal is to find the best dose and see how well the combination works. About 78 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug) and lenalidomide (a chemotherapy drug)
What this could lead to
If successful, this could offer a new treatment option for people with T-cell lymphoma that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
M D Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan-Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Thomas Jefferson University Hospital
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact